Axon Enterprise, Inc. (NASDAQ:AXON) Holdings Lowered by 17 Capital Partners LLC

17 Capital Partners LLC lowered its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,713 shares of the biotechnology company’s stock after selling 47 shares during the quarter. 17 Capital Partners LLC’s holdings in Axon Enterprise were worth $1,084,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of AXON. Vanguard Group Inc. lifted its holdings in shares of Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares in the last quarter. Motley Fool Asset Management LLC grew its position in Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after acquiring an additional 346,838 shares in the last quarter. 1832 Asset Management L.P. increased its stake in shares of Axon Enterprise by 44.0% during the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after purchasing an additional 114,800 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Axon Enterprise by 13.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock valued at $108,496,000 after purchasing an additional 45,049 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in shares of Axon Enterprise by 1.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock valued at $79,571,000 after purchasing an additional 4,365 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the transaction, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, President Joshua Isner sold 25,811 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the sale, the president now owns 228,166 shares of the company’s stock, valued at $82,103,253.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the transaction, the director now owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 369,172 shares of company stock valued at $136,270,842 over the last three months. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $603.18 on Friday. The firm’s 50-day moving average is $414.16 and its 200-day moving average is $347.27. The company has a market cap of $45.58 billion, a price-to-earnings ratio of 155.86, a PEG ratio of 15.15 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise, Inc. has a 52-week low of $212.88 and a 52-week high of $611.88.

Analyst Upgrades and Downgrades

Several research firms have commented on AXON. Northland Securities increased their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. The Goldman Sachs Group raised their price objective on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. JMP Securities upped their target price on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC lifted their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday. Finally, Robert W. Baird boosted their price objective on shares of Axon Enterprise from $440.00 to $460.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $412.42.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.